Clinical Trials · NCT02588404

The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

Name: The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

WithdrawnN/AGonadorelin

Phase: N/A
Recruitment status: Withdrawn
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Enrollment: 0
Start date: Dec 2015
Locations: See registry
Primary endpoint: Number of patients with biochemical failure showing presence of TMPRSS2-ERG gene fusion.

View Gonadorelin compound reference